Celldex’s Barzolvolimab: Promising Phase 2 Results and Market Potential Justify Buy Rating

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Celldex (CLDX – Research Report), with a price target of $74.00.

Sam Slutsky has given his Buy rating due to a combination of factors surrounding Celldex’s promising clinical data and potential market opportunities. The recent 76-week results from Celldex’s Phase 2 study of barzolvolimab for chronic spontaneous urticaria (CSU) have shown impressive durability and efficacy, even after the treatment was stopped at week 48. A significant percentage of patients maintained a complete response or well-controlled disease status at week 76, which is unprecedented compared to other CSU treatments currently available or in development.
Moreover, the data suggests that Celldex’s treatment could lead to individualized dosing strategies, potentially allowing some patients to achieve treatment-free remission intervals. This opens up opportunities for future maintenance dosing intervals that could enhance the tolerability profile of KIT inhibitors. Additionally, the improvement in patients’ quality of life and the normalization of serum tryptase levels further support the potential of barzolvolimab as a transformative treatment option, justifying the Buy rating.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $50.00 price target.